TG Therapeutics Provides Preliminary Fourth Quarter and Full-Year Financial Results in SEC Filing

TG Therapeutics Inc., a Delaware-based biopharmaceutical company (NASDAQ: TGTX), recently released preliminary financial information for the fourth quarter and full year of 2024 alongside anticipated development milestones for 2025. The company submitted this announcement in a recent 8-K filing to the U.S. Securities and Exchange Commission (SEC).

According to the filing made on January 14, 2025, TG Therapeutics issued a press release titled “TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones.” The press release outlines key insights into the company’s financial performance and future plans, aiming to keep investors informed.

While the press release was attached as Exhibit 99.1 to the filing, it’s essential to note that the information shared in the 8-K filing, including the press release, is considered furnished information and not filed with the SEC under Section 18 of the Securities Exchange Act of 1934. Therefore, it is not subject to regulatory liabilities or deemed incorporated by reference into subsequent filings unless expressly indicated in the future.

Additionally, the filing detailed the registration of TG Therapeutics’ Common Stock (Ticker Symbol: TGTX) on the Nasdaq Capital Market.

The company’s upcoming milestones for 2025 were briefly outlined in the press release, covering anticipated developments and possibly further diversification in its pipeline or product offerings.

This disclosure establishes transparency for investors, offering a glimpse into the company’s financial performance and strategic direction for the year ahead.

In addition, the filing further highlighted the compensation and employment agreement between TG Therapeutics and one of its executives, Craig W. Best, outlining terms and conditions of a Restricted Stock Grant covered under the 2019 Omnibus Stock Incentive Plan.

The agreement provided details on the vesting schedule, Participant’s rights and privileges, non-compete and non-solicitation clauses, investment requirements, forfeiture clauses, and arbitration procedures among others. It emphasized restrictions on disclosing company-confidential information and adherence to ethical practices.

TG Therapeutics underscored its commitment to aligning executive compensation with business objectives and enhancing corporate governance through regulatory compliance and transparent communication with shareholders.

Investors and stakeholders are encouraged to review the 8-K filing in its entirety to glean a more comprehensive understanding of TG Therapeutics’ financial performance and future prospects based on the disclosed information.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read TG Therapeutics’s 8K filing here.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.